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ABSTRACT 
Rationale: Long-term macrolide therapy can result in clinical improvement in 
patients with severe chronic inflammatory lung diseases associated with 
frequent bacterial colonization and chronic infection. 
Objective: To determine wether long-term azithromycin therapy reduces 
exacerbation frequency in severe chronic obstructive pulmonary disease 
(COPD) 
Methods: Retrospective observational study to assess the clinical  benefits of 
long-term azithromycin therapy (500 mg orally three times per week) over 12 
months in severe COPD patients with a minimum of 4 acute exacerbations 
(AECOPD) per year or colonized by Pseudomonas aeruginosa and comparing 
with the previous 12 months: the number of AECOPD, hospitalizations and days 
of hospital stay. Patients were classified into three groups according to the 
previous  baseline colonization: group 1, common microorganisms; group 2, 
colonized by P.aeruginosa and group 3 alternate common microorganisms and 
P.aeruginosa. 
Measurments and main results: We include 24 patients, all men, mean (SD) 
age 70.9 (7.4) years, FEV1 0.95 L (32.2%). The patients had 7.0 (3.0) 
AECOPD, 3.3 (2.0) hospitalizations and 43.0 (26.2) days of hospital stay in the 
year before recruitment. Four patients did not complete the 12 months of 
treatment, only one had to be withdrawn related to side effects (dyspepsia). We 
analyzed 20 patients who completed  the year of treatment (35% group 1, 45% 
group 2 and 20% group3). Long-term azithromycin therapy reduced significantly 
(year before versus year with azithromycin): AECOPD 6,8 (2,8) vs 2,8 (2,5) 
p=0,000; hospitalizations 3,6 (1,4) vs 1,4 (1,5) p=0,001 and days of hospital 
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stay 43,7 (21,4) vs 25 (32,2) p=0,013. Analyzing by subgroups the improvement 
was particularly significant in group 1 patients with common microorganisms 
with a 70% reduction in AECOPD and hospitalizations. Group 2 and 3 also 
improved highlighting those colonized by P.aeruginosa with 43% and 47% 
reduction in AECOPD and hospitalizations respectively. 
Conclusions: Long-term azithromycin is associated with a significant reduction 
of AECOPD, hospitalizations and days of hospital stay in patients with severe 
COPD and repeated AECOPD independently to baseline colonization. 
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INTRODUCTION:  
 Chronic obstructive pulmonary disease (COPD) is associated with the 
presence of acute exacerbations (AECOPD) [1] . Mortality risk increases with 
the frequency of AECOPD especially when patients require hospitalization [2, 
3]. Bacterial infections are likely etiologic for approximately 50%  of AECOPD 
[4]. Recently there has been greater interest in the use of prophylactic 
antibiotics to prevent AECOPD [5].  Macrolides have both antibacterial and 
antiinflamatory properties. Long-term macrolide therapy is routinely used in two 
diseases that involve chronic airway inflammation such as diffuse 
panbronchiolitis and cystic fibrosis (CF). In diffuse panbronchiolitis, 
erythromycin has been the most commonly used macrolide, showing 
remarkably improvement in survival and symptoms [6]. Studies in CF have used 
mostly azithromycin showing improvements in lung function and reduction in 
exacerbation frequency [7, 8], the effect is probably due to modulation of the 
inflammatory response and the ability of azithromycin to impede biofilm 
formation being recommended in chronic bronchial infection by Pseudomonas 
species [9] [10]. 
Given the importance of inflammation [11] and bacterial infection in the 
pathogenesis of COPD it has been proposed that macrolides may offer unique 
advantages as disease modifying agents. There are only two studies that 
analyze the effectiveness and safety of long-term erithromycin in COPD over a 
periods of 12 months with a significant reduction in moderate to severe 
AECOPD [12, 13]. Remains to be defined if the terapeutic effect reflect 
antimicrobial activity, an immunomodulatory effect, or both.  
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Azithromycin, the prototypical 15 member-ring macrolide, appears to have a 
better safety profile and dosage  for its long-term use as well as improved 
bacteriological activity, especially in bronchial colonization by P.aeruginosa, 
with regards to erythromycin. 
We report in this article the usefulness of long-term azithromycin therapy to 
reduce exacerbation frequency in severe COPD patients that despite being 
treated maximally with conventional therapies are in high-risk of AECOPD; the 
therapeutic effect according to baseline colonization by P.aeruginosa or 
common microorganisms and its impact on bacteriology and development of 
resistance to macrolides. 
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METHODS 
 Retrospective observational study in patients with severe COPD 
controlled in the respiratory day hospital of the Sabadell hospital (Barcelona, 
Spain) (March 2007-August 2009) to assess the clinical  benefits of long-term 
azithromycin therapy (500 mg orally three times per week) for 12 months to 
reduce AECOPD frequency.  
The inclusion criteria were patients with severe COPD  (FEV1< 50% of 
predicted) with a minimum of 4 AECOPD in the year prior to start azithromycin 
or patients with chronic bronchial colonization by P.aeruginosa.  
Patients with asthma, bronchiectasis, malignancies, unstable heart disease or 
liver disease were excluded.  In the recruitment pulmonary function tests and 
oxygen therapy at home were noted. All patients underwent the same clinical 
control in the respiratory day hospital  before and after starting long-term 
azithromycin and all were treated with long-term beta-agonists, anticholinergics 
and inhaled corticosteroids. Colimycin inhaled therapy was noted in those with 
chronic colonization by P.aeruginosa . 
Patients were classified into three groups according to the potentially 
pathogenic microorganisms (ppm) isolated from sputum samples during the 
AECOPD in the year prior to start azithromycin: Group 1, patients with common 
microorganisms (Haemophilus influenzae, Streptococcus pneumoniae and 
Moraxella catarrhalis); group 2, patients with chronic bronchial colonization by 
P.aeruginosa and group 3 patients that alternate common microorganisms and 
P aeruginosa but without bronchial colonization. 
 We compare the period of 12 months of treatment with azithromycin with the 
previous 12 months, overall and by groups, the following parameters: number of 
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AECOPD, hospitalizations and days of hospitalization for AECOPD. It also 
discusses the evolution of bacterial infection in each group and the 
development of resistance of ppm to azithromycin before and after long-term 
therapy with azithromycin. 
 
Definition and treatment of exacerbations: 
AECOPD is defined as a sustained worsening of the patient’s condition, from 
the stable state and beyond normal day to day variations, that is acute in onset 
and necessitates a change in regular treatment (oral corticosteroids and/or 
antibiotics and/or hospital admission) in a patient with underlying COPD [14].  
AECOPD were attended from Monday to Friday (8:00 to 17:00 hours) at the 
respiratory day hospital always by the same team of pulmonologists [15]. 
Outside these hours AECOPD were attended in the emergency department with 
the reviewing of the emergency reports.  
 
Definition of chronic bronchial colonization by P.aeruginosa: 
Presence of three or more consecutive sputum cultures of P.aeruginosa 
isolated in a period of 6 months, in samples separated by at least 1 month in 
clinically stable patients [16] .  
 
Statistical analysis: 
Quantitative variables are expressed as mean ± standard deviation. Statistical 
analysis is performed using Student t test for paired data. All statistical tests 
were performed with a confidence level of 95%. 
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Results: 
 We include 24 patients with severe COPD, all men, mean age (SD) 70.9 
(7.4) years. Pulmonary function tests showed, mean (% predicted), FVC 2.43 
liters (58.8%), FEV1 0.95 liters (32.2%), and FEV1/FVC ratio 39%. Five patients 
(20.8%) used chronic domiciliary oxygen therapy. 
 In the 12 months prior to the start of azithromycin these patients had a 
mean (SD) of 7.0 (3.0) AECOPD, 3.3 (2.0) hospitalizations and 43.0 (26.2) days 
of hospital stay. Four patients did not complete 12 months with azithromycin. Of 
these four one was withdrawn for dyspepsia, one for diagnosis of malignancy 
during the follow-up and the other two discontinued the treatment unrelated to 
side effects.  
 We analyze the twenty patients who completed 12 months of treatment 
with azithromycin . In the 12 months prior to the start of azithromycin these  
patients had a total of 136 AECOPD, of which 72 (52,9%) were severe requiring 
hospitalization. Long-term azithromycin therapy resulted in a significant 
reduction of AECOPD and hospitalizations by a total of 57 and 28 respectively 
which represents an average reduction of 58.9% AECOPD and 61.2% 
hospitalizations; together with a reduction of 18.7 days in the mean hospital stay 
(See table I). 
According to the ppm isolated in sputum samples during the year prior to start 
azithromycin 7 patients were included in group 1 with common microorganisms,  
9 patients in  group 2 with chronic bronchial colonization by P.aeruginosa (of 
these 5 (55,5%) were in colimycin inhaled therapy) and 4 patients in group 3 
alternating common microorganisms and P.aeruginosa. Long-term azithromycin 
therapy reduced in all groups the number of AECOPD, hospitalizations and 
 9
days of hospital length stay. This reduction was particularly significant in the 
group of common microorganisms with a 70% reduction of AECOPD and 
hospitalizations; and reduction of 25 days in the mean hospital stay. In the 
P.aeruginosa group a statistically significant reduction in AECOPD of 43,5% 
was also observerd and in terms of hospitalizations and hospital stay despite a 
decrease of 47,1% and 32,5% respectively these not reach statistical 
significance. The alternating group improved in all parameters studied, althoug  
their small size did not allow statistically significant differences (See table I). 
 
 
Variable 
 
0-12 months 
WITHOUT 
AZITHROMYCIN 
12-24 months 
WITH 
AZITHROMYCIN 
GLOBAL N  Total Mean ± sd Total Mean ± sd Red 
% 
p 
Number of exacerbations 20 136 6.8 ± 2.8 57 2.8 ± 2.5 58,9 0.000 
Number of hospitalizations 20 72 3.6 ± 1.9 28 1.4 ± 1.5 61,2 0.001 
Days of hospital stay 20 874 43.7 ± 21.4 500 25.0 ± 32.2 42,8 0.013 
COMMON 
MICROORGANISMS 
 Total Mean ± sd Total Mean ± sd Red 
% 
p 
Number of exacerbations 7 63 9.0 ± 2.3 19 2.7 ± 2.2 70 0.00 
Number of hospitalizations 7 29 4.1 ± 2.6 9 1.2 ± 1.4 70,8 0.04 
Days of hospital stay 7 309 44.1 ± 17.5 133 19 ± 25 57 0.05 
PSEUDOMONAS 
AERUGINOSA 
 Total Mean ± sd Total Mean ± sd Red 
% 
p 
Number of exacerbations 9 42 4.6 ± 2.2 24 2.6 ± 2.0 43,5 0.04 
Number of hospitalizations 9 31 3.4 ± 1.6 17 1.8 ± 1.7 47,1 0.08 
Days of hospital stay 9 454 50.4 ± 23.9 306 34.0 ± 38.5 32,5 0.23 
ALTERNATE  Total Mean ± sd Total Mean ± sd Red 
% 
p 
Number of exacerbations 4 31 7.7 ± 0.5 14 3.5 ± 4.4 54,6 0.14 
Number of hospitalizations 4 12 3.0 ± 1.4 2 0.5 ± 1.0 83,3 0.09 
Days of hospital stay 4 111 27.7 ± 17.0 61 15.2 ± 30.5 45,2 0.27 
TABLE I: Number of AECOPD, hospitalizations and days of hospitalization with and without 
azithromycin, globally and according to the group of potentially pathogenic microorganisms 
(ppm) isolated from sputum samples before and initiation of azithromycin. (N: Number of 
patients; SD: Standard derivation; % Red: Percentage of reduction). 
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Figure I: Number of AECOPD before and after long-term azithromycin according to the group of 
potentially pathogenic microorganisms (ppm) isolated from sputum (Pre-AZT: Before long-term 
azithromycin, Post AZT:After long-term azithromycin ). 
 
  
Long term azithromycin therapy  negativized the sputum cultures in 9 of 
20 patients during follow-up; 4 corresponded to the common microorganisms 
group, 4 corresponded to the chronic bronchial colonization by P aeruginosa 
group, without significant association to the presence of mucoid forms or to be 
in colimycin inhaled therapy, and 1 to the alternating group.  Azithromycin 
eradicated the common microorganisms in the alternating group, being 
observed in 3 of the 4 patients only P aeruginosa isolates during the follow-up 
with  long-term azithromycin. In only 1 patient of common microorganisms 
group P aeruginosa was isolated during long-term azithromycin therapy (See 
table II). 
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12-24 months WITH AZITHROMYCIN 
  NEGATIVE 
CULTURES 
COMMON 
MICROORGANISMS P. AERUGINOSA TOTAL 
COMMON 
MICROORGANISMS 4 2 1 7
P. AERUGINOSA 4 0 5 9
 
0-12 months 
WITHOUT 
AZITHROMYCIN 
ALTERNATE 1 0 3 4
                                                     TOTAL 9 2 9 20
TABLE II: Classification of patients according to the group of potentially pathogenic 
microorganisms (ppm) isolated from sputum samples before and after initiation long-term 
azithromycin therapy. 
 
 
  
AECOPD with sputum culture isolates of common microorganism were 
reduced from 31 (22,7%) of a global 136 to 5 (8,7%) of a global 57 AECOPD 
during long-term azithromycin therapy. 
In Table 3 we can see the sensitivity of common microorganisms to macrolides 
before and after long-term azithromycin therapy. Of note that all strains of 
H.influenzae isolated were resistant to erythromycin whereas none was against 
azithromycin before starting treatment and that the strains of S.pneumoniae 
resistant to macrolides were also resistant to clindamycin  showing a highly 
resistant phenotype. 
Regarding the bactericidal effect of long-term azithromycin therapy  on common 
microorganisms and the development of bacterial resistance against it, we did 
not observe any isolate of Mcatharralis during the follow-up, a single isolate of 
H.influenzae that had developed resistance to azithromycin and four isolates of 
S.pneumoniae all resistant to azithromycin. 
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Erythromycin  Clarithromycin  Azithromycin  0-12 months 
WITHOUT AZITHROMYCIN 
SEN INT RES SEN INT RES SEN INT RES 
Nº isolates 
pre-AZT 
0 0 10 7 2 1 10 0 0 10 (31,3%)
3 0 3 3 0 3 3 0 3 6 (18,8%) 
Haemophilus influenzae 
Streptococcus pneumoniae 
Moraxella catharralis 14 1 1 15 0 1 15 0 0 15 (50%) 
Erythromycin  Clarithromycin  Azithromycin  
12-24 months 
WITH AZITHROMYCIN 
SEN INT RES SEN INT RES SEN INT RES 
Nº isolates 
post-AZT 
0 0 1 0 0 1 0 0 1 1 (20%) 
0 0 4 0 0 4 0 0 4 4 (80%) 
Haemophilus influenzae 
Streptococcus pneumoniae 
Moraxella catharralis 0 0 0 0 0 0 0 0 0 0  
TABLE 3: Common microorganisms isolated in sputum cultures during exacerbations before 
and after starting Azithromycin and its antibiogram to macrolides (SEN: Sensitive, INT: 
intermediate, RES: resistant, Nº isolates pre-AZT: Number of isolates previous azithromycin 
therapy, Nº isolates post-AZT: Number of isolates post azithromycin therapy) 
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Discusion: 
 This is the first study that evaluates  the usefulness of long-term 
azithromycin therapy, for a period of 12-months, in patients with severe  COPD  
and repeated AECOPD to reduce the exacerbation frequency and its 
therapeutic effect according to baseline colonization.  
The weekly dosage of azithromycin used, one tablet of 500 mgr three times a 
week (monday, wednesday and friday) is the standard used in patients with 
bronchiectasis associated to Cystic fibrosis and chronic bronchial colonization 
by Pseudomonas aeruginosa [17]. 
Our results show that long-term azithromycin therapy in patients with severe 
COPD and repeated AECOPD reduce very significantly to less than half the 
number of AECOPD and hospitalizations and secondarily the days of hospital 
stay. The treatment was well tolerated over the 1-year period of treatment 
having to be removed in only one patient for dyspepsia. 
The potential utility of long-term macrolide therapy in COPD is supported mainly 
by two published studies, both with erythromycin and for a period of 12 months, 
with a significant reduction in the number and severity of the AECOPD [12, 13].  
First, Suzuki and colleagues reported results of an open-label, prospective 
randomized trial (not blinded) of erythromycin therapy (200-400mgr/day) versus 
non active treatment for twelve months in 109 COPD patients (FEV1=1,4 liters); 
they found an increased relative risk of experiencing an AECOPD in the control 
group versus erythromycin group of 4.71 (95% CI, 1.53 to 14.5; p = 0.007) and 
more severe AECOPD in the control group than in the erythromycin group (p = 
0.0007). Second, Seemungal and colleagues, in a single-center, randomized 
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controlled trial, administered erythromycin (250 mg, twice daily) or placebo for 1 
year to 109 patients with moderate to severe COPD (mean FEV1 = 50% of 
predicted). The primary outcome was the frequency of AECOPD that required 
antibiotics, oral corticosteroids, or hospitalization. Erythromycin reduced 
AECOPD in relative terms by 35% and increased median time to first 
exacerbation from 89 to 271 days, both differences being statistically significant.  
All patients included in our study had severe COPD with a minimum of four 
AECOPD during the year prior to start azithromycin while Semungal and 
colleagues included patients with moderate to severe COPD, of them only 35% 
had three or more AECOPD during the year prior to inclusion.  
In our opinion azithromycin offers clinical advantages over erythromycin. 
Regarding its metabolism doesn’t interfere with the metabolic pathway of 
cytochrome P450 , which prevent possible metabolic interferences with other 
drugs that share the same pathway and are often used in COPD such as 
steroids and theophylline; has better digestive tolerance;  has less 
hepatotoxicity and it isn’t associated with long QT syndrome what makes it 
better tolerated with a better safety profile and dosage for its long-term use [18, 
19]. Despite macrolides provide adequate coverage for the most frequently 
common microorganisms identified in AECOPD there are differences in 
H.influenzae activity. Azithromycin, the prototypical 15 member ring macrolide, 
appears to have improved bacteriological and clinical activity relative to 14-
membered ring macrolides such as erithromycin and clarithromycin [20]. 
Observe that in our study all strains of H.influenzae isolated previous to start 
long-term azithromycin were resistant to erithromycin while none to 
azithromycin. 
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The subgroup analysis shows that those patients with AECOPD for common 
microorganisms (Group 1), despite being the group with a greater number of 
AECOPD and hospitalizations prior to start azithromycin, are the group that 
improved more with long-term azithromycin therapy by a very significant 70% 
reduction in AECOPD and hospitalizations. The mechanism of improvement 
could be related to the antibacterial activity of azithromycin  particularly with 
regards to H.influenzae and M.catharralis, AECOPD with isolates for these 
microorganisms were reduced from a total of 25 pre-azithromycin to just one for 
H.influenza during long-term azithromycin therapy. We did not observe this level 
of bacterial erradication for S.pneumoniae with higher prevalence of resistance 
to azithromycin. However we can not exclude that the improvement observed 
may be due in part to anti-inflammatory and immunomodulatory properties of 
azithromycin [21]. Azithromycin could decrease the sputum volume and its 
viscoelasticity and increase mucociliary transport [22, 23]. Refer also the  ability 
of azithromycin to accumulate in the neutrophil interfering with chemotaxis  to 
the  inflammatory focus and promoting neutrophil apoptosis and clearance by 
macrophages [24, 25]. Seemungal et al in its trial with long-term erithromycin 
analyzed as secondary outcomes inflammatory mediators in sputum (IL-6, IL-8 
and myeloperoxidase) and plasma (IL-6, IL-8 and C-reactive protein) without 
finding no statistically significant treatment-related differences [13]. Lack of an 
erythromycin effect on inflammatory markers suggests that antimicrobial effects 
might be the more important. However, no causal linkage has been established 
between the inflammatory markers measured in this study and exacerbation 
frequency.  
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Patients with more advanced COPD and specially those with repeated courses 
of antibiotic therapy, hospital admisions or oral corticosteroids have an 
increased risk of exacerbations caused by P.aeruginosa [26, 27]. This is 
important because antibiotic treatment decisions should be stratified according 
to the severity of AECOPD with risk factors for P.aeruginosa isolation [28].  
When analyzing our patients with chronic bronchial colonization by 
P.aeruginosa (group 2) these represent 45% of patients included wich reflects  
the severity of COPD. In these patients long-term azithromycin therapy  
improved all the outcomes analyzed by a statistically significant  43% reduction 
in AECOPD. Hospitalizations and days of hospital stay were also reduced to 
47% and 32% respectively although not reach statistical signification.  
It is known the role of macrolides, mainly azithromycin, in the treatment of 
chronic bronchial colonization by P.aeruginosa in patients with bronchiectasis, 
especially those associated with cystic fibrosis [7, 29]. Azithromycin interferes 
with P.aeruginosa quorum sensing and  its production of virulence factors [30]; 
reduces biofilm formation  by inhibiting alginate production and decreases 
bacterial adherence [31]. For these reasons we think that long-term 
azithromycin is also specially indicated in these group of patients. The reduction 
in hospitalizations and days of mean hospital stay  is less evident in these group 
of patients because often  require hospitalization to receive parenteral 
antibiotics due to P.aeruginosa resistance to oral antibiotics. Interestingly in 4 of 
these 9 patients colonized there were no isolates in sputum samples during 
long-term azithromycin therapy follow-up without relation to be on colymicin 
inhaled therapy.  
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When analyzing group 3 patients that alternate common microorganisms and 
P.aeruginosa without bronchial colonization we can observe how long-term 
azithromycin therapy eradicates common microorganisms during follow up and 
reduces too AECOPD, hospitalizations and days of hospital stay.  However the 
small group size did not allow statistically significant differences. 
The potential limitations of our study are the absence of a control group and the 
small number of patients included. 
In conclusion, we have shown that long-term azithromycin, at a dosage of 500 
mgr three times a week, is associated with a significant reduction of AECOPD, 
hospitalizations and days of mean hospital stay in patients with severe COPD 
and repeated AECOPD. This improvement is especially significant in patients 
with AECOPD for common microorganisms due to its antibacterial activity but 
also in those with chronic bronchial colonization by Pseudomonas aeruginosa 
providing important properties as an inmunomodulatiry agent and preventing 
AECOPD for common microorganisms. Long-term azithromycin may be 
reserved in severe COPD patients at high risk of exacerbations. 
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